- Email: [email protected]
20 Donor apheresis activities around the world: results of an international survey
Abstracts of Swisstransfusion 2010, Joint Congress of WAA, ESFH, BTS/SRC, SATM / Transfusion and Apheresis Science 43 (2010) S1–S27
Conclusion: These results suggest that the apheresis therapies by GMA and LCAP systems may be selected as a standard therapy for active UC. 20 Donor apheresis activities around the world: results of an international survey R. Moog. Bernau, DE Background: Donor apheresis procedures differ widely in most centres. Standardisation of procedures, unique quality of components collected and education not only on a national level but on an international level will be a help for the apheresis community. Aim: To get information about donor apheresis activities in different countries. Using this information international standards for donor apheresis procedures, product quality and staff education can be established on an consensual basis. Methods: An international survey with questions about the existence of an apheresis society or a special apheresis interest group, the number of donor apheresis procedures per year, parameters of product quality, staff education, donor registry and research activities was sent out to national key persons working in the field of apheresis. If the survey was not returned within 4 weeks a second and thereafter a third send out was done. Data were evaluated with descriptive statistics. Results: Up to now 33% of the surveys were sent back. Ten countries reported on apheresis societies or special interest groups with activities in apheresis research and development, promotion of apheresis guidelines and standard as well as education. Apheresis guidelines are available in 55% of the countries and they are updated within 1–3 years. Education of donor apheresis staff is implemented and organized by institutes, special interest groups, and corporations. The number of plateletphereses ranged from 0 in countries with limited resources to 1,500,000 in high developed countries. Standard platelet doses were different in the surveyed countries and defined with ranges from 1.5–4.8×1011 per unit. Double platelet dose collection was frequently implemented but triple dose platelet collection showed to be a new procedure under current investigation. Plasmaphereses were the most often performed apheresis procedures with a collected standard plasma volume of 500–660 mL. Red blood cell collection by apheresis is poorly implemented and has no impact for the blood supply. Only some countries reported on data about allogeneic blood stem cell (33%), multicomponent collection (22%) and granulocyte collections (11%). Data about donor side effects were collected in 50% of the surveyed countries but publication of these results was poor. Reported research activities focused on adverse events, optimization of apheresis procedures, product quality, donor epidemiology and recruitment. Conclusion: The evaluation of the survey showed that staff education, blood components collected and research activities differed widely all over the world. National apheresis societies and special interest groups should work together to unify future standardization of guidelines, staff education and product parameters to guarantee a good product quality of apheresis components.
S7
5 Triple platelet dose collection is a safe and feasible apheresis procedure R. Moog. Bernau, DE Background: Modern blood cell separators allow for the collection of high dose platelet concentrates. This helps to maximize platelet production, increase platelet availability and minimize production cost. Aim: To evaluate triple dose platelet collection with respect to safety and feasibility. Methods: 60 healthy donors fulfilling European and German recommendations for cytapheresis were included in the study. Donors were allowed to donate every 2 weeks. 480 plateletphereses using the Trima Accel™ blood cell separator were performed targeting to collect a triple platelet dose. Platelets were counted electronically before and after apheresis and in platelet concentrates. A target dose of 7.2–9.0×1011 was adjusted to obtain 3 platelet doses with a minimum of 2×1011 per unit. Furthermore, donors were monitored for adverse events. Results: Triple dose platelet collection was achieved in 96% according to European and national guidelines. Average platelet dose was 2.6×1011 in a mean product volume of 230 mL. Mean donor platelet count before apheresis was 303±64/nl and decreased to 195±48/nl after plateletpheresis. The lowest platelet count after apheresis was 111/nl. 21 donor adverse events were observed (4.4%) including circulatory reactions (1.9%) and haematomas (1.5%) resulting in a termination of apheresis. Summary/conclusion: Triple dose platelet collection is an economical tool to increase the platelet supply. Triple platelet doses can be collected in high percentage of donors with a high platelet pre-count. Provided that donors are carefully checked for triple dose eligibility the number of adverse events is not higher than in standard plateletpheresis. Therefore, triple dose platelet collection is considered as an economical and safe procedure. 34 Mononuclear cell collection in patients treated with extracorporeal photochemotherapy by using the off-line method: a comparison between COBE Spectra AutoPbsc version 6.1 and Amicus cell separators P. Perseghin, A. Incontri. Monza, IT Background: The first step (MNC collection) during extracorporeal photochemotherapy by using the off-line method, is of paramount importance, since the product should be highly MNC-enriched with low RBC count to avoid UV-A intercepting by erythrocytes. Material and Methods: 10 patients (9 with chronic GvHD and 1 with bullous pemphigoid) underwent MNC collection on subsequent days either with the COBE Spectra AutoPbsc v 6.1 or the Amicus Crescendo cell separator. Total and differential WBC count were performed on peripheral blood samples before procedure and on the yields. The procedure parameters were recorded for comparison between the two devices. Analysis included descriptive statistics and paired t-test.
Conclusion: These results suggest that the apheresis therapies by GMA and LCAP systems may be selected as a standard therapy for active UC. 20 Donor apheresis activities around the world: results of an international survey R. Moog. Bernau, DE Background: Donor apheresis procedures differ widely in most centres. Standardisation of procedures, unique quality of components collected and education not only on a national level but on an international level will be a help for the apheresis community. Aim: To get information about donor apheresis activities in different countries. Using this information international standards for donor apheresis procedures, product quality and staff education can be established on an consensual basis. Methods: An international survey with questions about the existence of an apheresis society or a special apheresis interest group, the number of donor apheresis procedures per year, parameters of product quality, staff education, donor registry and research activities was sent out to national key persons working in the field of apheresis. If the survey was not returned within 4 weeks a second and thereafter a third send out was done. Data were evaluated with descriptive statistics. Results: Up to now 33% of the surveys were sent back. Ten countries reported on apheresis societies or special interest groups with activities in apheresis research and development, promotion of apheresis guidelines and standard as well as education. Apheresis guidelines are available in 55% of the countries and they are updated within 1–3 years. Education of donor apheresis staff is implemented and organized by institutes, special interest groups, and corporations. The number of plateletphereses ranged from 0 in countries with limited resources to 1,500,000 in high developed countries. Standard platelet doses were different in the surveyed countries and defined with ranges from 1.5–4.8×1011 per unit. Double platelet dose collection was frequently implemented but triple dose platelet collection showed to be a new procedure under current investigation. Plasmaphereses were the most often performed apheresis procedures with a collected standard plasma volume of 500–660 mL. Red blood cell collection by apheresis is poorly implemented and has no impact for the blood supply. Only some countries reported on data about allogeneic blood stem cell (33%), multicomponent collection (22%) and granulocyte collections (11%). Data about donor side effects were collected in 50% of the surveyed countries but publication of these results was poor. Reported research activities focused on adverse events, optimization of apheresis procedures, product quality, donor epidemiology and recruitment. Conclusion: The evaluation of the survey showed that staff education, blood components collected and research activities differed widely all over the world. National apheresis societies and special interest groups should work together to unify future standardization of guidelines, staff education and product parameters to guarantee a good product quality of apheresis components.
S7
5 Triple platelet dose collection is a safe and feasible apheresis procedure R. Moog. Bernau, DE Background: Modern blood cell separators allow for the collection of high dose platelet concentrates. This helps to maximize platelet production, increase platelet availability and minimize production cost. Aim: To evaluate triple dose platelet collection with respect to safety and feasibility. Methods: 60 healthy donors fulfilling European and German recommendations for cytapheresis were included in the study. Donors were allowed to donate every 2 weeks. 480 plateletphereses using the Trima Accel™ blood cell separator were performed targeting to collect a triple platelet dose. Platelets were counted electronically before and after apheresis and in platelet concentrates. A target dose of 7.2–9.0×1011 was adjusted to obtain 3 platelet doses with a minimum of 2×1011 per unit. Furthermore, donors were monitored for adverse events. Results: Triple dose platelet collection was achieved in 96% according to European and national guidelines. Average platelet dose was 2.6×1011 in a mean product volume of 230 mL. Mean donor platelet count before apheresis was 303±64/nl and decreased to 195±48/nl after plateletpheresis. The lowest platelet count after apheresis was 111/nl. 21 donor adverse events were observed (4.4%) including circulatory reactions (1.9%) and haematomas (1.5%) resulting in a termination of apheresis. Summary/conclusion: Triple dose platelet collection is an economical tool to increase the platelet supply. Triple platelet doses can be collected in high percentage of donors with a high platelet pre-count. Provided that donors are carefully checked for triple dose eligibility the number of adverse events is not higher than in standard plateletpheresis. Therefore, triple dose platelet collection is considered as an economical and safe procedure. 34 Mononuclear cell collection in patients treated with extracorporeal photochemotherapy by using the off-line method: a comparison between COBE Spectra AutoPbsc version 6.1 and Amicus cell separators P. Perseghin, A. Incontri. Monza, IT Background: The first step (MNC collection) during extracorporeal photochemotherapy by using the off-line method, is of paramount importance, since the product should be highly MNC-enriched with low RBC count to avoid UV-A intercepting by erythrocytes. Material and Methods: 10 patients (9 with chronic GvHD and 1 with bullous pemphigoid) underwent MNC collection on subsequent days either with the COBE Spectra AutoPbsc v 6.1 or the Amicus Crescendo cell separator. Total and differential WBC count were performed on peripheral blood samples before procedure and on the yields. The procedure parameters were recorded for comparison between the two devices. Analysis included descriptive statistics and paired t-test.